Login to Your Account



Race to the Finish Line

Abbott Going Toe to Toe with Gilead in Oral HCV Regimen

By Marie Powers
Staff Writer

Friday, October 12, 2012
In recent months, Gilead Sciences Inc. appeared to be in the driver's seat in the race for an all-oral, interferon-free hepatitis C virus (HCV) regimen. However, Abbott's posting of the first Phase III trial of its combination HCV regimen on ClinicalTrials.gov puts Gilead on notice that it won't cross the finish line unchallenged.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription